title: Persistence of nevirapine in breast milk after discontinuation of treatment.
abstract: The objective of this study was to serially quantitate the concentration of nevirapine in breast milk after discontinuation of treatment. Samples were collected from both breasts of a human immunodeficiency virus-infected patient for 3 weeks. Nevirapine was quantifiable for up to 17 days after discontinuation of therapy; total nevirapine concentrations remained above the 90% inhibitory concentration for 6 days, and no differences were observed between breasts.
authors.affiliation: Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294-0019, USA.
authors.forename: Chantelle
authors.initials: C
authors.lastname: Bennetto-Hood
authors.forename: Grace M
authors.initials: GM
authors.lastname: Aldrovandi
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: King
authors.forename: Kyra
authors.initials: K
authors.lastname: Woodman
authors.forename: Negar
authors.initials: N
authors.lastname: Ashouri
authors.forename: Edward P
authors.initials: EP
authors.lastname: Acosta
mesh_terms: D019380:Anti-HIV Agents / Q000302:isolation & purification* / Q000627:therapeutic use; D005260:Female; D007839:Functional Laterality; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008895:Milk, Human / Q000737:chemistry*; D019829:Nevirapine / Q000302:isolation & purification* / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine